NASDAQ:MRNS
Marinus Pharmaceuticals Stock News
$1.30
-0.0300 (-2.26%)
At Close: May 16, 2024
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceut
After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)
10:36am, Thursday, 16'th May 2024
Marinus Pharmaceuticals (MRNS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earn
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceut
LOS ANGELES, CA / ACCESSWIRE / May 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceut
LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuti
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
09:31am, Wednesday, 08'th May 2024
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.68 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.67 per share a year ago.
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 08'th May 2024
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
08:00am, Thursday, 02'nd May 2024
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASD
LOS ANGELES, CA / ACCESSWIRE / April 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Marinus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MRNS
05:00am, Monday, 22'nd Apr 2024
NEW YORK, NY / ACCESSWIRE / April 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
LOS ANGELES, CA / ACCESSWIRE / April 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Investors who lost money on Marinus Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - MRNS
08:00am, Sunday, 21'st Apr 2024
NEW YORK, NY / ACCESSWIRE / April 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
LOS ANGELES, CA / ACCESSWIRE / April 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Marinus Pharmaceuticals, Inc. (MRNS)
04:50am, Friday, 19'th Apr 2024
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Marinus Pharmaceuticals, Inc. ("Marinus Pharmaceuticals, Inc.") (NASDAQ:MRNS)
